A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus
Latest Information Update: 22 Dec 2021
At a glance
- Drugs Ocrelizumab (Primary) ; Immunosuppressants; Prednisone
- Indications Systemic lupus erythematosus
- Focus Registrational; Therapeutic Use
- Acronyms BEGIN
- Sponsors Genentech; Roche
- 26 Jun 2012 Additional locations added as reported by European Clinical Trials Database record.
- 09 Mar 2010 Trial has been halted since May 2008 due to serious and opportunistic infections signals, as reported by media releases from Roche and Biogen Idec.
- 09 Mar 2010 Trial has been halted since May 2008 due to serious and opportunistic infections signals, as reported by media releases from Roche and Biogen Idec.